Objectives: A mechanism for the acquisition of high-level echinocandin resistance in Candida glabrata was investigated. FKS mutants were constructed to: determine whether clinically significant micafungin resistance requires a hot-spot mutation in FKS1 and a premature stop codon in FKS2, as was observed in a clinical isolate; select for variants with reduced susceptibility and locate mutations in FKS genes; and assess the roles of FKS1 and FKS2.
Introduction
The proportion of systemic fungal infections in humans caused by non-albicans Candida species has increased significantly in the past two decades. Candida glabrata has displaced Candida parapsilosis as the second most frequently isolated species in cases of candidiasis in North America and Europe, possibly because 20% of C. glabrata isolates are innately resistant to the widely used triazole antifungals 1 and the organism can rapidly acquire azole resistance during therapy. 2, 3 The echinocandins (caspofungin, micafungin and anidulafungin) are semisynthetic, non-competitive b-1,3-glucan synthase (GS) inhibitors, and are effective against Candida and Aspergillus species. They do not appear to be substrates of pleiotropic drug resistance drug efflux pumps 4 and provide new treatment options for systemic fungal infections caused by azole-resistant species such as C. glabrata. Although the incidence of echinocandin-resistant fungal pathogens remains low, 5 -7 an association between resistance or reduced susceptibility and single amino acid changes in the echinocandin resistance regions (hot spots) of the GS catalytic subunits has been well documented in studies of echinocandin-resistant clinical isolates and laboratory strains of Candida albicans 8 -10 or C. glabrata. 11 -15 In addition to reports of clinical isolates with high MICs of echinocandins, other isolates show an intermediate level of resistance. 7, 11 This phenomenon has not been explained, although a linkage between phenotype and the amino acid substitution position has been suggested. 16 When highly resistant mutants are reported in the clinic, many cases occur after a second echinocandin treatment. 6 We believe that elucidation of the mechanisms of how fungal pathogens acquire echinocandin resistance should lead to better clinical outcomes, and has important implications for antifungal drug discovery and development.
The plasma membrane enzyme GS, responsible for the synthesis of the essential cell wall component b-1,3-glucan, is found in limiting quantities at sites of cell expansion in vegetatively growing yeast cells and in the hyphal tips of filamentous fungi. 17, 18 The core of the GS protein complex is thought to consist of at least one catalytic subunit (Fksp) and the regulatory subunit (Rho1p), but other proteins may interact with the complex or have a role in echinocandin binding or susceptibility. 19 Three putative catalytic subunits of GS [FKS1 (CAGL0G01 034g), FKS2 (CAGL0K04037g) and FKS3 (CAGL0M13827g)] have been identified in the C. glabrata genome database (http:// www.genolevures.org/elt/CAGL/CAGL). Synteny analysis and amino acid sequence similarities ( Figure S1a and b, available as Supplementary data at JAC Online) showed that C. glabrata FKS1 and FKS2 encode proteins that correspond to Fks1p (FKS1: YLR342W) and Fks2p (FKS2: YGR032W) from the closely related species Saccharomyces cerevisiae. ScFks3p (FKS3: YMR306W) is considered to localize in mitochondria, 20 and its orthologue, CgFks3p, is expressed at trace levels 11 and has a significantly lower amino acid identity to Fks1p and Fks2p ( Figure S1a ). There has been no report of hot-spot mutations in C. glabrata FKS3. DNA sequence analysis of FKS1, FKS2 and the regulatory subunit RHO1 (CAGL0I08459g) from a micafungin-resistant C. glabrata clinical isolate 21 and a micafungin-susceptible reference strain detected an amino acid change in hot spot 1 in FKS1, plus a single nucleotide change predicted to introduce a premature stop codon into FKS2. The finding that a homozygous hot-spot mutation in GSC1 (also known as FKS1) alleles of the diploid yeast C. albicans conferred significantly higher resistance to echinocandins than a heterozygous mutation was consistent with a semi-dominant phenotype. 22 A multistep mechanism for the development of high-level, clinically significant, micafungin resistance is consistent with the available epidemiological evidence. 6 We hypothesized that this type of micafungin resistance could be acquired in a multistep process that requires a single nucleotide change in both FKS genes. This was tested by constructing a panel of C. glabrata mutant strains that possess a single mutation in FKS1 alone or in FKS2 alone, or single mutations in both FKS1 and FKS2, by using auxotrophic parents derived from the database strain CBS138. C. glabrata mutants with individual FKS genes deleted (Dfks1 or Dfks2) and a tetracycline-regulated mutant (Dfks1 tet-FKS2) were used to determine the contribution of specific GS subunits to cell physiology. This study provides evidence that in our laboratory mutants severely reduced susceptibility is acquired in a stepwise manner. Whether this phenomenon is common in highly resistant clinical isolates of C. glabrata remains to be established.
Materials and methods

Strains and culture conditions
The C. glabrata and S. cerevisiae strains used in this study are listed in Table 1 . Two separate parental strains (NAU3 and 2001HT) derived from the C. glabrata database strain CBS138 were employed due to the requirement for three auxotrophic markers in constructing a panel of mutants. Cells were maintained on yeast extract/peptone/dextrose (YPD) agar plates containing 1% (w/v) Bacto yeast extract (Becton, Dickinson and Company, Sparks, MD, USA), 2% (w/v) Bacto peptone (Becton, Dickinson and Company), 2% (w/v) glucose and 2% (w/v) agar at pH 5.5.
Chemicals
Micafungin and FK506 were obtained from Astellas Pharma Inc. (Osaka, Japan). Caspofungin was a gift from Merck & Co., Inc. (Rahway, NJ, USA). Fluconazole was purchased from Pfizer Laboratories Limited (Auckland, New Zealand). Nystatin and doxycycline were from Sigma (St Louis, MO, USA), and 5-fluoroorotic acid was purchased from Wako Pure Chemical Industries Ltd (Osaka, Japan).
Antifungal susceptibility tests
Liquid microdilution MIC determinations were performed in triplicate, in at least three independent experiments, in accordance with the CLSI document M27-A2, with minor modifications. Log-phase yeast cells were used for MIC determination in RPMI 1640 (Sigma). For growth of strain NAU3, uridine (100 mg/L) was added to RPMI medium. Cell growth was monitored as optical density (OD) at 590 nm using an EL340 Bio Kinetics plate reader (BioTek Instruments Inc., Winooski, VT, USA). The MICs for the C. glabrata strains were determined after 24 h of incubation at 358C with shaking at 150 rpm. The MICs of azoles, echinocandins and nystatin were the concentrations of the drug giving .80%, .90% and 100% inhibition of cell growth, respectively, compared with the no-drug control.
DNA sequence analysis of FKS1, FKS2 and RHO1
Complete open reading frames (ORFs) of FKS1, FKS2 and RHO1 were PCR amplified from genomic DNA using KOD DNA polymerase (Toyobo Osaka, Japan or Novagen, San Diego, CA, USA) and a set of primers (Table S1 , available as Supplementary data at JAC Online) designed using sequences for the C. glabrata database strain CBS138 (http:// www.genolevures.org/elt/CAGL/CAGL). DNA was purified using QIAGEN purification columns (QIAGEN Pty Ltd, Victoria, Australia). DNA sequencing was performed using the BigDye TM Terminator Version 3.1 Ready Reaction Cycle Sequencing Kit (Applied Biosystems Inc., Foster City, CA, USA) and a Capillary ABI3730 Genetic Analyzer (Applied Biosystems Inc.). GenBank accession numbers for FKS1, FKS2 and RHO1 from the strain CBS138 are XM_446406, XM_448401 and XM_447616, respectively.
Construction of the Ura 2 auxotrophic strain NAU3
A DNA fragment containing the C. glabrata URA3 ORF and its flanking regions was PCR amplified from genomic DNA of strain CBS138 using
Mechanisms of micafungin resistance in Candida glabrata primers CgURA3F and CgURA3R (Table S1) , and cloned into pUC19 at SmaI and BamHI sites to yield the plasmid pUC-URA3. The URA3 ORF was then replaced with a lacZ fragment (322 bp) obtained from pUC19 by digesting with PvuII, and cloning into EcoRV and StuI sites of the pUC-URA3 to create a plasmid pUC-UinZ. A transformation cassette containing lacZ flanked by sequences upstream and downstream of URA3 was PCR amplified from pUC-UinZ using the primer set CgURA3F and CgURA3R, and used to transform CBS138. Ura 2 transformants were selected on synthetic medium [0.67% (w/v) yeast nitrogen base (YNB; Difco, Becton, Dickinson and Company), 2% (w/v) glucose and 2% (w/v) agar, pH 7.0] containing 0.2% 5-fluoroorotic acid. Susceptible strains harbouring the lacZ disruption of the URA3 locus were selected using complementation by the URA3-harbouring centromeric plasmid pACU [a gift from Dr Kitada, Chugai Pharmaceutical Co., Ltd (formerly Nippon Roche Research Center), Kanagawa, Japan]. The strain NAU3, which harboured pACU and grew on synthetic medium in the absence of uracil, was selected.
Construction of site-directed FKS mutants
Strains with a single mutation in either FKS1 or FKS2 and with FKS1-FKS2 double mutations were constructed by site-directed mutagenesis using 2001HT or NAU3 as the parent strain and the primers listed in Table S1 . All PCRs were performed using KOD DNA polymerase. Cells grown to exponential phase were transformed with 2 -5 mg of DNA using the lithium acetate method. 23 The S629P mutation was introduced into the hot spot of the FKS1 gene in the micafungin-susceptible auxotroph 2001HT. A 6 kb DNA fragment containing the FKS1 ORF plus the 3 ′ non-coding region was PCR amplified from genomic DNA of clinical isolate 4872 using the primer set FKSG-F and FKSG-R (Table S1 ). A 1.2 kb DNA fragment containing the ScHIS3 ORF and its flanking regions was PCR amplified from genomic DNA of S. cerevisiae AH22 using primers ScHIS3-F and ScHIS3-R. The S. cerevisiae HIS3 was used as a selection marker due to the relatively high identity (72% at the amino acid level) between the HIS3 genes from the two species and to avoid non-targeted integration of the CgHIS3 flanking regions. A 0.5 kb DNA fragment containing the 3 ′ downstream region of FKS1 was PCR amplified from genomic DNA of strain 2001HT using primers FKSG3 ′ fhis-F and FKSG3
′ f-R, and joined to the 1.2 kb fragment to give a 1.7 kb DNA fragment. The 6 and 1.7 kb fragments were used to co-transform strain 2001HT, and His + transformants were selected on complete supplement medium (CSM) containing 0.67% (w/v) YNB, 0.077% (w/v) CSM without histidine (BIO 101, Irvine, CA, USA), 2% (w/v) glucose and 2% (w/v) agar. The correct construct, confirmed by colony PCR and DNA sequencing of FKS1, was designated strain H10. The strain had the nucleotide change T1885C in FKS1, but no nucleotide changes in FKS2 or RHO1.
A strain possessing mutations in both FKS1 and FKS2 was created in mutant H10 by introducing the nucleotide change (C4638G) predicted to introduce a premature stop codon into FKS2. A 1.9 kb FKS2 ORF containing the C4638G change and a 0.5 kb 3 ′ non-coding region was PCR amplified from genomic DNA of strain 4872 using the primer set FKSK.8 and FKSK.R2. A 2.1 kb fragment containing the S. cerevisiae TRP1 ORF and its flanking regions were PCR amplified from genomic DNA of strain AH22 using primers ScTRP1-F and ScTRP1-R. The ScTRP1 gene was used as a selection maker because it is functional in C. glabrata, despite amino acid identity between CgTRP1 and ScTRP1 being only 52.5%. 24 A 0.5 kb fragment downstream in the FKS2 3 ′ non-coding region was PCR amplified from 2001HT using primers FKSK3 ′ ftrp1-F2 and FKSK3 ′ f-R. The three fragments were then fused by recombinant PCR to obtain a 4.5 kb transformation cassette and used to transform H10 to the double mutant H10T13, which was selected for Trp + on CSM minus tryptophan (BIO 101). DNA sequence analysis of FKS2 from H10T13 confirmed the mutation C4638G and five synonymous single nucleotide polymorphisms (SNPs) in common with strain 4872. The DNA sequences of FKS1 and RHO1 were identical to those in strain H10.
Strain G17, possessing a single premature stop codon in FKS2, was constructed using the Ura 2 auxotroph NAU3 and three DNA fragments: the 2.4 kb DNA fragment used to construct the double mutant H10T13; the selection marker ScURA3 and its flanking regions PCR amplified from genomic DNA of S. cerevisiae AH22 using the primers URA3pro Niimi et al.
and URA3FKS2-3 ′ fF; and a 0.5 kb 3 ′ non-coding region of FKS2 amplified from genomic DNA of NAU3 using the primers FKS2FDF and FKSK3 ′ f-R. These fragments were fused by recombinant PCR to make a transformation cassette. Transformants were initially selected for Ura + on CSM agar minus uracil (BIO 101). The desired transformant was identified by abolition of a SnaBI restriction site in FKS2 due to the C4638G nucleotide change. DNA sequencing confirmed the C4638G change in FKS2 and the absence of nucleotide changes in the FKS1 of strain G17 compared with NAU3.
The FKS1 and FKS2 deletants (Dfks1 and Dfks2) were constructed using strain NAU3, as depicted in Figure S2 (available as Supplementary data at JAC Online). Fragments of 0.5 kb comprising upstream and downstream non-coding regions of FKS1 or FKS2 were PCR amplified from NAU3 genomic DNA and fused with ScURA3 PCR amplified from genomic DNA of S. cerevisiae AH22. The resultant transformation cassettes were used to replace the ORF of either FKS1 or FKS2. Ura + transformants were selected and deletion of the ORF was confirmed by colony PCR and DNA sequence analysis.
Construction of a strain with tetracycline-regulated FKS2 in the Dfks1 background Strain TPOP910043 (HIS3-tetp-FKS2) possessing the tetracyclineresponsive promoter upstream of the FKS2 ORF was constructed using strain ACG4. 25 Plasmid p99CGH 25 was modified by introducing the sequences GGCCGCTGATCACG and CCAGCCTCACGATG into the regions flanking HIS3-99t, which contains the HIS3 selection marker and a tetracycline promoter, 99t. The resultant plasmid, pTK916-99t, and the primer set p10043F and p10043TR (Table S1 ), which had 56 bp sequences overlapping with the FKS2 promoter and ORF, respectively, were used to PCR amplify the DNA fragment HIS3-99t ( Figure S3a , available as Supplementary data at JAC Online). This fragment was used to transform strain ACG4 and then histidine prototrophs were selected. PCR analysis confirmed the correct integration of the fragment in strain TPOP910043. The FKS1 ORF was then deleted in strain TPOP910043 to construct strain T910043_K10047 with the HIS3-tetp-FKS2 Dfks1::SAT1 genotype. The DNA fragments 10047-L and 10047-R, corresponding to sequences upstream and downstream of the FKS1 ORF, respectively, were PCR amplified from genomic DNA of ACG4 by using the primer sets p10047-1 and p10047-2 for 10047-L, and p10047-3 and p10047-4 for 10047-R amplifications ( Figure S3b , available as Supplementary data at JAC Online). A DNA fragment containing SAT1 26 was PCR amplified from plasmid pSFS2A (a gift from Dr O. Reuss, Institut fü r Molekulare Infektionsbiologie, Universitä t Wü rzburg, Wü rzburg, Germany) using primers pSAT1-completeF1 and pSAT1-completeR1. This fragment was fused to 10047-L and to 10047-R individually using primers p10047-1 and pSAT1-completeR1, and p10047-4 and pSAT1-completeF1 to create fragments 10047-L-SAT1 and 10047-R-SAT1, respectively, by recombinant PCR ( Figure S3b ). These fragments were used to co-transform strain TPOP910043 ( Figure S3c , available as Supplementary data at JAC Online) and then correct transformants were selected for nourseothricin resistance. PCR analysis confirmed the deletion of the FKS1 ORF in strain T910043_K10047.
Selection of variants with reduced micafungin susceptibility from C. glabrata mutants Variants of C. glabrata mutants with reduced micafungin susceptibility were selected by exposing cells to micafungin using agarose diffusion assays. Discs containing various amounts of micafungin were placed on 20 mL of YPD agarose medium containing 2×10 5 cells and then incubated at 308C for up to 4 weeks. For mutant strains that did not produce resistant variants on solid medium, cells (2×10 7 cells/mL) were incubated in YPD liquid medium containing micafungin (4-16× MIC) at 308C for 48 h with shaking at 200 rpm, and a portion of growth-positive culture was spread on YPD agar containing the same concentration of micafungin as above. Colonies grown on the micafungin-containing YPD medium were isolated, their drug susceptibility measured and the DNA sequences of their FKS genes determined.
RNA extraction and gene expression profiling by RT-PCR
Cells were grown in YPD medium at 378C overnight with shaking at 125 rpm and inoculated in fresh YPD at an OD 600 of 0.25 ( 5×10 6 cells/mL). When cell growth reached an OD 600 of 1.0 (early log phase) or OD 600 of 10 (late log phase), a 2 mL sample was harvested by centrifugation and immediately suspended in 600 mL of RLT buffer (RNeasy Mini Kit, QIAGEN) with an equal volume of 0.5 mm glass beads. The cells were disrupted with a Multi-Beads Shocker (Yasui Kikai Corporation, Japan) by using five cycles of disruption at 2700 rpm for 15 s separated by 3 s intervals with no shaking. Total RNA was extracted from 125 mL of lysate using the RNeasy Mini Kit, with inclusion of on-column RNase-Free DNase treatment for 60 min. Reverse transcription was carried out using a combination of random hexamers and oligo(dT) primers following prescribed reaction conditions (PrimeScript RT Reagent Kit and Perfect Real Time Kit, TaKaRa, Japan) using 320 ng of template RNA per 20 mL reaction. For endpoint RT-PCR, TaKaRa Ex Taq and primers (Table S1) were used to amplify 100 bp products within the ORF of each gene. The primers were designed to have similar melting temperatures. Primer specificity was determined experimentally prior to the RT-PCR.
Preparation of GS and GS inhibition assay
Cells were grown in YPD with vigorous shaking (200 rpm) at 378C until an OD 600 of 10, representing the late log phase. Cell disruption, membrane preparation and GS inhibition assays were performed according to the method previously described. 22 Control reactions were performed without micafungin to calculate 100% UDP-glucose incorporation or with trichloroacetic acid added to the reaction at time zero to calculate 0% incorporation. Inhibition curves and 50% inhibitory concentrations (IC 50 s) were obtained using GraphPad Prism (version 4.03) software (GraphPad Software, San Diego, CA, USA) using a two-site competition fitting algorithm or sigmoidal response curves.
Nucleotide sequence accession numbers
The full nucleotide sequences of the C. glabrata FKS1, FKS2 and RHO1 from strains 4872 and ATCC 90030 determined in this study have been deposited in GenBank (http://www.ncbi.nlm.nih.gov/genbank) with the following accession numbers: FKS1 from 4872 (HM366439) and ATCC 90030 (HM366440); FKS2 from 4872 (HM366441) and ATCC 90030 (HM366442); and RHO1 from 4872 (HM366443) and ATCC 90030 (HM366444).
Results
Characterization of a micafungin-resistant clinical isolate
The micafungin MIC in RPMI medium for the micafunginresistant clinical isolate, 4872, was 2 mg/L, the same MIC value as was previously reported for this strain. 21 This was .100-fold higher than that for the control micafungin-susceptible strain ATCC 90030 (0.0156 mg/L). The isolate showed cross-resistance to caspofungin ( Table 2) . As expected, both strains showed similar susceptibilities to the azole antifungal fluconazole and the polyene antifungal nystatin ( Table 2) .
Mechanisms of micafungin resistance in Candida glabrata
1669 JAC DNA sequence analysis of the complete ORF of FKS1, FKS2 and RHO1 from ATCC 90030 found no amino acid changes in comparison with database strain CBS138. The database strain and strain 4872 differed in 19 SNPs in FKS1, of which T1885C was the only non-synonymous nucleotide change. This nucleotide change predicted the amino acid substitution S629P within hot spot 1 (amino acid positions 625 -633) of echinocandin-resistant C. glabrata clinical isolates.
11 DNA sequencing of the FKS2 ORF revealed 15 SNPs between the database strain and strain 4872. Fourteen of the SNPs were synonymous, but one SNP (C4638G) was predicted to introduce a stop codon (TAG) that would truncate the protein after amino acid 1546 (the Fks2p primary sequence consists of 1897 amino acids). The FKS2 gene had no nucleotide changes in either hot spot 1 (amino acid positions 659-667) or hot spot 2 (1374 -1381). The RHO1 genes from ATCC 90030 and strain 4872 contained four synonymous SNPs at nucleotide positions 276, 342, 420 and 528 relative to the ATG start codon and no nonsynonymous SNPs.
In the diploid fungal pathogen C. albicans, echinocandinresistant clinical isolates and laboratory mutants were obtained with a homozygous mutation in the hot spot of the GS catalytic subunit GSC1. 22 The significantly (4-fold) higher resistance of the homozygous mutation compared with the heterozygous mutation indicated a semi-dominant phenotype. For the haploid organism C. glabrata, we therefore hypothesized that single mutations in FKS1 or FKS2 may also give a semi-dominant phenotype and that mutations in both genes would be required to confer clinically significant severely reduced susceptibility to micafungin. As no micafungin-susceptible isogenic parent of the clinical isolate was available, this hypothesis was tested by reproducing the mutations detected in the micafungin-resistant clinical isolate, 4872, in micafungin-susceptible strains using sitedirected mutagenesis.
Antifungal susceptibilities of mutant strains
The auxotrophic parent strains 2001HT and NAU3 used to make constructs had the same micafungin MICs as the micafunginsusceptible reference strain, ATCC 90030 (0.0156 mg/L, Table 2 ). The introduction of the hot-spot mutation T1885C in FKS1 (strain H10) conferred an intermediate level of reduced susceptibility to micafungin (0.125 mg/L, Table 2 ). Thus, a single nucleotide change in the hot spot of FKS1 alone was insufficient to confer the severely reduced micafungin susceptibility found in clinical isolate 4872. Introduction of the premature stop codon C4638G into FKS2 (strain G17) alone had no effect on echinocandin susceptibility (micafungin MIC¼ 0.0156 mg/L). However, the T1885C mutation in FKS1 plus the C4638G mutation in FKS2 (strain H10T13) conferred severely reduced susceptibility (MIC¼ 2 mg/L, Table 2 ) equivalent to that of clinical isolate 4872. These results implied that fully functional Fks1p S629P does not require Fks2p and/or the enzyme activity of the mutant Fks1p was up-regulated in the absence of functional Fks2p. As expected, strain H10T13 showed cross-resistance to caspofungin, but not to fluconazole or nystatin ( Table 2 ).
The stability of the reduced micafungin susceptibility phenotype was tested by subculturing strains H10, H10T13 and 4872 on YPD agar plates in the absence of micafungin for 50 passages. Retention of the reduced micafungin susceptibility phenotype by strains 4872, H10 and H10T13 in the absence of selection pressure implies that the mutations in FKS1 and FKS2 are stable (data not shown).
Antifungal susceptibilities of FKS deletants
Strains with FKS1 deleted (Dfks1, retaining FKS2) or with FKS2 deleted (Dfks2, retaining FKS1) showed similar growth rates (between 131 and 153 min doubling time in RPMI medium), growth yields (between OD 600 of 3.46 and 3.75 after 48 h of incubation in RPMI medium) and susceptibilities to micafungin, azoles or the calcineurin inhibitor FK506 as their parental strain (Table 2 ). Attempts to create a Dfks1Dfks2 double knockout were unsuccessful, probably due to lethality of the double deletion. This hypothesis was tested by creating a tetracycline-regulated FKS2 in a Dfks1 background. When 10 5 cells/mL (OD 600 ¼ 0.01) was used as the initial inoculum, the cell density in YPD liquid medium reached .4×10
8 cells/mL after 3 days of incubation at 358C in the absence of doxycycline. The addition of doxycycline (100 mg/L) did not kill control C. glabrata cells, but stopped the growth of the mutant strain. Viable cell counts declined to ,10 2 cells/mL after 3 days of incubation. This confirmed that the FKS1-FKS2 double deletion is lethal to C. glabrata.
Selection of variants with reduced micafungin susceptibility from C. glabrata mutants
All micafungin-susceptible strains tested (ATCC 90030, 2001HT, NAU3, G17 and the single deletants Dfks1 and Dfks2) remained susceptible to micafungin and no variants with reduced susceptibility appeared in the inhibitory zones of micafungin (0.5-4 mg/disc) in agarose diffusion assays after prolonged incubation ( 4 weeks). The micafungin-resistant strains 4872 and H10T13 showed severely reduced susceptibility, and no variants with an Niimi et al.
even stronger phenotype appeared within 4 weeks (2-16 mg/disc). In contrast, the H10 strain, which showed an intermediate reduction in susceptibility in liquid MIC assays, gave a two-step growth profile around the discs of micafungin (4 mg/disc). After 24 h of incubation, a zone of weak growth surrounding a clear zone appeared, and after 4 days of incubation H10 produced several large colonies in the clear and weak inhibitory zones (Figure 1a) . Those colonies were isolated and characterized. In liquid RPMI medium, all seven H10 variants (H10Vs) tested had micafungin MICs between 2 and 4 mg/L (Table 3) . Each variant had lower susceptibility to micafungin than the parent H10 and had the same level of MIC as clinical isolate 4872. DNA sequence analysis of the entire FKS2 gene of six H10V clones detected single nucleotide changes that predicted either a premature stop codon (Figure 1b) or a single amino acid change (Figure 1c ). The single amino acid changes were distributed throughout the ORF, including one at amino acid position 1378 within hot spot 2 in clone H10 V2 (Figure 1c) . The nucleotide positions of the stop codon mutations in the FKS2 genes were different from that detected in FKS2 of strain 4872 (Figure 1b) . A 4 bp insertion at nucleotide position 5010 of the remaining clone tested (H10 V1) caused a frame shift that resulted in a premature stop codon at position 5069. The FKS1 genes from the variants were unchanged in sequence, with retention of the hot-spot mutation in FKS1. These results suggested that the single amino acid changes encoded in the FKS1 hot spot together with the stop codon mutations or single amino acid changes encoded in FKS2 confer severely reduced micafungin susceptibility functionally equivalent to that in strain 4872. When liquid YPD containing micafungin was used, strains NAU3, G17, Dfks1 and Dfks2 were able to produce variants with reduced susceptibility, probably due to the fact that a higher cell density (2×10 7 cells/mL) was used than in the agarose diffusion assays. Cells exposed to micafungin at 4 -16-fold higher concentrations than their MIC developed severely reduced micafungin susceptibility after 48 h of incubation at 308C. Variants of the wild-type susceptible strain NAU3 acquired mutations in hot spot 1, but only in FKS1. Strain G17 and the Dfks1 and Dfks2 variants acquired mutations predicted to affect the hot spots in their remaining functional GS subunit (Table 3 ). All variants showed an increased MIC of micafungin (Table 3) . Strain H10T13 and clinical isolate 4872 did not produce variants with further reduced susceptibility to micafungin.
Expression of FKS in FKS mutant strains
The expression of the FKS1 and FKS2 genes in cells harvested at the early and late log phase was monitored using RT-PCR with ACT1 as an internal control (Figure 2 Mechanisms of micafungin resistance in Candida glabrata 1671 JAC significant difference in the expression of the two genes between these strains. The premature stop codon in FKS2 did not alter FKS2 or FKS1 mRNA expression in strain H10T13 (Figure 2 ), G17 or clinical isolate 4872 (data not shown). Control RT-PCR in the absence of reverse transcriptase and using primers specific to C. glabrata FKS1 confirmed that contamination of genomic DNA in the RNA preparations was not significant and efficiencies of the primer sets used were all similar (data not shown). Studies of early log-phase cells (OD 600 ¼ 1.0) showed slightly higher ratios of FKS1/FKS2 expression (1.97+0.39 in 2001HT, 2.41+0.37 in H10 and 2.79+0.42 in H10T13, Figure 2 ) compared with those in late log-phase cells. These results suggest that the relative expression of FKS1 and FKS2 is growth-phase dependent, consistent with earlier studies in S. cerevisiae.
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Inhibition of GS activity by micafungin
Kinetic analysis of the GS enzymes from micafungin-susceptible parent 2001HT, the single mutant H10 and the double mutant H10T13 showed that GS from H10 had lower K m values and GS activity than preparations from 2001HT and H10T13 ( Figure 3b and Table 4 ). GS activity from susceptible strain 2001HT showed an inhibition profile for both micafungin-sensitive Fks1p and Fks2p subunits (Figure 3a) . The GS activity from H10T13 was highly resistant to micafungin and stimulated 10% by micafungin at low concentrations (Figure 3a) . It was partially inhibited by micafungin at drug concentrations .100 mg/L, possibly due to a detergent-like inactivation. The IC 50 of micafungin for this resistant GS was three orders of magnitude higher than for the sensitive GS (Table 4 ). The GS activity from strain H10 was inhibited by micafungin in a multiphasic manner that included a 5% stimulation of activity in the presence of low concentrations of micafungin and the detergent effect at drug concentrations .100 mg/L (Figure 3a and b) . It had two IC 50 values, one for sensitive Fks2p subunits and a second for resistant Fks1p subunits (Table 4) . It was possible to reconstitute the micafungin inhibition curve for strain H10 by hypothesizing a contribution to GS activity from the mutant Fks1p that was about 5-fold higher than the contribution from wild-type Fks2p (Figure 3b ) using a formula of T¼ (0.1×2001HT activity)+ (0.5×H10T13 activity).
Discussion
The amino acid mutation S629P in hot spot 1 of FKS1 of clinical isolate 4872 has been reported previously for a C. glabrata clinical isolate resistant to caspofungin and micafungin. 11 We used S629P  A352D  2  H10 V5  S629P  G1534S  2  H10 V6  S629P  T458K  4  H10 V7  S629P  stop codon  2 MCF, micafungin; WT, wild-type. H10Vs were obtained using micafungin agarose diffusion assays on solid medium (see Figure 1 ). Niimi et al.
site-directed mutagenesis to recreate the mutation and confirm that this serine-to-proline change is associated with micafungin resistance. The clinical isolate also contained a stop codon mutation in FKS2 that is predicted to truncate Fks2p. Since the co-expression of mutant Fks1p and wild-type Fks2p was found to confer a semi-dominant, intermediate level of reduced micafungin susceptibility only (in strain H10), further modification of Fks2p was needed to complete a stepwise development of a severely reduced susceptibility in the mutant strain H10T13. Analysis of our panel of laboratory mutants confirmed that the conferral of clinically significant severely reduced susceptibility to echinocandin on C. glabrata requires mutations in both FKS1 and FKS2, a result that excludes extragenic mutations or alterations in gene expression. The nature of resistance acquisition was probed using two mutants: strain H10 with the hot-spot mutation S629P in FKS1 and strain G17 with a premature stop codon in FKS2. The single mutation in FKS1 (H10) conferred an intermediate level of reduced susceptibility to micafungin and the stronger phenotype could then be developed by modification of FKS2, including the introduction of stop codons. Furthermore, the presence of a premature stop codon mutation in FKS2 alone did not reduce drug susceptibility (G17). It is therefore likely that the C. glabrata 4872 strain acquired the mutation in FKS1 and then the stop codon mutation in FKS2 upon further exposure to micafungin. This was substantiated by the selection of variants with severely reduced susceptibility to micafungin. The exposure of susceptible cells to micafungin at sublethal concentrations primarily selected for mutations that gave an amino acid change in the FKS1 hot spot 1. Further exposure of cells with intermediate micafungin resistance to the drug selected for changes in FKS2, which conferred severely reduced susceptibility. A stepwise acquisition of micafungin resistance was also observed in C. albicans upon exposure to micafungin. 22 The C. glabrata single mutant H10 readily developed severely reduced susceptibility on micafungin exposure. This suggests that FKS1 and FKS2 of C. glabrata behave as if each is equivalent to an allele of C. albicans GSC1, with the caveat that FKS1 is usually modified first. We suspect, but have yet to prove, that all the stop codon mutations outside the hot spots led to nonfunctional Fks2p, or the single amino acid changes led to either non-functional Fks2p or a conformational change in Fks2p that then affected the sensitivity of the GS enzyme to micafungin. The failure of the double mutant H10T13 to develop a further reduction in susceptibility to micafungin suggests that the FKS1-FKS2 double mutation confers maximally reduced susceptibility to micafungin.
It was anticipated that the deletion of FKS1 plus FKS2 would be lethal in C. glabrata, as was reported for the closely related species Reconstituted inhibition profile of GS from strain H10 (expressed using raw data to compare enzyme activities between the strains). The theoretically reconstituted line was generated using GraphPad Prism software. MCF, micafungin. Mechanisms of micafungin resistance in Candida glabrata S. cerevisiae. 28 The doxycycline-dependent induction of synthetic lethality, using a tetracycline-regulated knockdown of FKS2 in a Dfks1 background, confirmed that the double deletion is also lethal to C. glabrata and that FKS3 did not compensate for the loss of Fks2p catalytic subunit activity. Although S. cerevisiae requires FKS3 for spore wall assembly along with FKS2, 29 the role of FKS3 in C. glabrata is not known. FKS1 and FKS2 are considered to be paralogues resulting from the whole-genome duplication, because they share biological function and are individually non-essential, but show synthetic lethality. 30 The synthetic lethality of FKS1 plus FKS2 in C. glabrata confirms that Fks1p and Fks2p are alternative GS catalytic subunits with overlapping function. 28 However, unlike S. cerevisiae, 28 C. glabrata Fks1p and Fks2p had identical susceptibilities to FK506. This suggests that the physiological functions of FKS2 in C. glabrata and S. cerevisiae may differ.
Although RT-PCR is a semi-quantitative method, our mutant strains showed that FKS1 was more highly expressed than FKS2. Furthermore, there was no significant difference in the expression levels of the two genes between the mutants. In S. cerevisiae, FKS1 is expressed predominantly in the vegetative growth phase, while FKS2 is expressed in the absence of glucose, when cells sporulate and as a Ca 2+ -dependent response to calcineurin. 28 We found that our mutants had a slightly higher ratio of FKS1/FKS2 expression during the early log phase than during the late log phase, consistent with FKS2 expression becoming more important as cells enter stationary phase. Since C. glabrata does not sporulate, it is again suggested that FKS2 from the two yeast species may have functional differences.
Some echinocandin-resistant clinical isolates of C. glabrata appear to possess an amino acid substitution in FKS2 alone. 6, 11 In contrast to our mutant strains, this observation suggests that certain mutations (e.g. Fks2p S663P) may confer dominant phenotypes or that the possession of extragenic mutations may contribute to the resistance. Our hypothesis, therefore, is not necessarily correct for all echinocandin-resistant C. glabrata strains. The occurrence of hot-spot mutations in either gene could depend on their relative expression levels. Clinical isolates possessing hot-spot mutations in FKS2 genes express, in most cases, more FKS2 than FKS1, while isolates possessing the mutation in FKS1 express more FKS1 than FKS2.
11 Our mutant strains, derived from the database strain CBS138, express FKS1 at higher levels than FKS2. This is consistent with a likelihood that the stepwise acquisition of amino acid changes should occur in FKS1 first in our strains. However, it has yet to be established whether the relative expression of FKS1 or FKS2 causes selection for mutations in the more highly expressed gene, or if the mutation causes increased expression of the affected gene. This should be investigated in additional clinical isolates with high FKS2/FKS1 expression ratios.
Although FKS2 mRNA expression was detected in the mutant G17, H10T13 and clinical isolate 4872, the truncated Fks2p polypeptide in strain H10T13 is predicted to be 1546 amino acids and is unlikely to be functional. The weak in vitro micafungin inhibition profile in H10T13 membranes indicated that GS activity was contributed only by Fks1p S629P, until detergent effects at .100 mg/L micafungin overpowered the activity. Similar incomplete inhibition of GS by micafungin was seen for a micafunginresistant clinical isolate and laboratory mutants of C. albicans.
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In contrast, reconstitution of the inhibition profile for strain H10 indicated that sensitive Fks2p contributed 17% of GS activity and highly resistant Fks1p contributed 83% of GS activity (Figure 3b ). Although GS is thought to form multimeric complexes with the regulatory Rho1p subunit, it is not known whether the catalytic subunits operate as monomers or higher order complexes. In S. cerevisiae, FKS2 can replace the function of FKS1 when FKS1 is deleted, with Dfks1 causing a 5-fold increased sensitivity (IC 50 for GS) to echinocandins compared with that for its wild-type parent. 28 In contrast, the C. glabrata Dfks1 and Dfks2 strains had unaltered susceptibilities to micafungin and FK506 (Table 2 ). Since neither subunit appeared growth limiting while GS enzyme activities varied between wild-type and mutant strains, we suggest that both genes contribute to semi-dominant echinocandin resistance and post-translational control of GS activity may be important. Strain H10 produces two active GS complexes, one containing Fks1p S629P only and another containing Fks2p only. We hypothesize that H10 also produces an inactive GS complex containing both Fks1p S629P and Fks2p subunits. The acquisition of the hot-spot mutation in FKS1 may block proper formation of the GS enzyme containing Fks2p. The presence of an inactive Fks1p S629P-Fks2p complex explains why GS activity in H10 is lower than in the susceptible parental strain and is recovered in the highly resistant strain H10T13. This hypothesis awaits experimental testing using pull-down experiments.
Many studies of FKS genes have performed DNA sequence analysis around hot-spot regions only. 6, 12, 13, 15 For example, Zimbeck et al. 6 would not have detected the bulk of the stop codons our study has identified. The presence of nucleotide changes outside hot spots in clinical isolate 4872 and resistant variants derived from H10 suggests that DNA sequencing of the entire ORF of FKS1 and FKS2 is necessary to detect nonsynonymous nucleotide changes including premature stop codons that can contribute to micafungin resistance. We have indeed detected a single amino acid change (G1300D or K1357E) or a premature stop codon (at nucleotide position 3166) in the FKS2 genes from three other echinocandin-resistant clinical isolates that possess a hot-spot-1 mutation (S629P or R631G) in the FKS1 gene (K. Niimi, K. Maki, M. Niimi, B. C. Monk and R. D. Cannon, unpublished data). This indicates that the genotype of our clinical isolate is neither unique nor exceptional.
Although fungal cells appear to acquire mutations primarily in the drug target FKS genes, including the hot-spot-3 mutation that may contribute to innate resistance in fungi, 31 an FKS-independent echinocandin resistance has also been described. 32, 33 This suggests that other mechanisms of resistance have yet to be discovered.
Micafungin is now widely used for antifungal prophylaxis for high-risk patients. Our findings indicate that a suitable clinical window of micafungin concentration should be employed in both primary and secondary treatment. If strains with intermediate resistance to micafungin are generated in the primary treatment, the selection of fully resistant strains in a second treatment is more likely. 6 It is therefore important to identify semi-dominant intermediate resistance in patients who have previously been exposed to the echinocandins. We are grateful to Dr T. Aoyama (Suzuka National College of Technology, Mie, Japan) for synteny analysis of C. glabrata FKS genes and Dr T. Milne (University of Otago, Dunedin, New Zealand) for help with graphic analysis. We also thank Professor D. S. Perlin (University of Medicine and Dentistry of New Jersey, NJ, USA) for critical reading of the manuscript prior to submission.
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